Role of oxidative DNA damage in mitochondrial dysfunction and Huntington's disease pathogenesis

Free Radical Biology and Medicine

Volumn 62, Issue , 2013, Pages 102-110

  Ayala Peña, Sylvette ^a  

^a UNIVERSITY OF PUERTO RICO SCHOOL OF MEDICINE   (Puerto Rico)

Author keywords

DNA; DNA repair; Huntington's disease; Mitochondrial; Mitochondrial bioenergetics; Mitochondrial dysfunction; Oxidative stress

Indexed keywords

CREATINE KINASE; HUNTINGTIN; MITOCHONDRIAL DNA; PEROXIREDOXIN 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; POLYGLUTAMINE; REACTIVE OXYGEN METABOLITE; SIRTUIN 1; TRANSCRIPTION FACTOR NRF1; TRANSCRIPTION FACTOR NRF2;

BRAIN CORTEX; CAG REPEAT; CELL DEATH; CORPUS STRIATUM; DISEASE COURSE; DISEASE SEVERITY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DNA DAMAGE; DNA REPAIR; DNA STRAND BREAKAGE; ENZYME ACTIVITY; HUMAN; HUNTINGTON CHOREA; IN VIVO STUDY; MISMATCH REPAIR; MITOCHONDRIAL ENERGY TRANSFER; MITOCHONDRIAL RESPIRATION; MOTOR PERFORMANCE; NERVE FIBER TRANSPORT; NONHUMAN; OXIDATIVE PHOSPHORYLATION; OXIDATIVE STRESS; PATHOGENESIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN EXPRESSION; RESPIRATORY CHAIN; REVIEW; SURVIVAL;

EID: 84884910504     PISSN: 08915849     EISSN: 18734596     Source Type: Journal    
DOI: 10.1016/j.freeradbiomed.2013.04.017     Document Type: Review

References (150)

1. Gusella, J. F.; Wexler, N. S.; Conneally, P. M.; Naylor, S. L.; Anderson, M. A.; Tanzi, R. E.; Watkins, P. C; Ottina, K.; Wallace, M. R.; Sakaguchi, A. Y., et al. A polymorphic DNA marker genetically linked to Huntington's disease. Nature 306: 234-238; 1983. (Pubitemid 14232350)
2. Huntington's Disease Collaborative Research Group A novel gene containing a trinucleotide repeat that is unstable on Huntington's Disease chromosomes. Cell 72: 971-983; 1993.
3. Andrew, S.; Theilmann, J.; Almqvist, E.; Norremolle, A.; Lucotte, G.; Anvret, M.; Sorensen, S.; Turpin, J.; Hayden, M. DNA analysis of distinct populations suggests multiple origins for the mutation causing Huntington disease. Clin. Genet. 43: 286-294; 1993. (Pubitemid 23217154)
4. Duyao, M.; Ambrose, C; Myers, R.; Novelletto, A.; Persichetti, F.; Frontali, M.; Folstein, S.; Ross, C; Franz, M.; Abbott, M. Trinucleotide repeat length instability and age of onset in Huntington's disease. Nat. Genet. 4: 673-676; 1993.
5. Snell, R.; MacMillan, J.; Cheadle, J.; Fenton, I.; Lazarou, L.; Davies, P.; MacDonald, M.; Gusella, J.; Harper, P.; Shaw, D. Relationship between trinucleotide repeat expansion and phenotypic variation in Huntington's disease. Nat. Genet. 4: 393-397; 1993. (Pubitemid 23231489)
6. Kremer, B.; Goldberg, P.; Andrew, S. E.; Theilmann, J.; Telenius, H.; Zeisler, J.; Squitieri, F.; Lin, B.; Bassett, A.; Almqvist, E., et al. A worldwide study of the Huntington's disease mutation. The sensitivity and specificity of measuring CAG repeats. N. Engl. J. Med. 330: 1401-1406; 1994.
7. Butterworth, N. J.; Williams, L; Bullock, J. Y.; Love, D. R.; Faull, R. L; Dragunow, M. Trinucleotide (CAG) repeat length is positively correlated with the degree of DNA fragmentation in Huntington's disease striatum. Neuroscience 87: 49-53; 1998. (Pubitemid 28351167)
8. Furtado, S.; Suchowersky, O.; Rewcastle, B.; Graham, L; Klimek, M.; Garber, A. Relationship between trinucleotide repeats and neuropathological changes in Huntington's disease. Ann. Neurol. 39: 132-136; 1996. (Pubitemid 26052228)
9. Ravina, B.; Romer, M.; Constantinescu, R.; Biglan, K.; Brocht, A.; Kieburtz, K.; Shoulson, I.; McDermott, M. The relationship between CAG repeat length and clinical progression in Huntington's disease. Mov. Disord 23: 1223-1227; 2008.
10. Foroud, T; Gray, J.; Ivashina, J.; Conneally, P. M. Differences in duration of Huntington's disease based on age at onset. J. Neurol. Neurosurg. Psychiatry 66: 52-56; 1999. (Pubitemid 29101487)
11. Martin, J. B.; Gusella, J. F. Huntington's disease. Pathogenesis and management. N. Engl. J. Med. 315: 1267-1276; 1986.
12. Paulsen, J.; Conybeare, R. Cognitive changes in Huntington's disease. Adv. Neurol. 96: 209-225; 2005.
13. Kumar, P.; Kalonia, H.; Kumar, A. Huntington's disease: pathogenesis to animal models. Pharmacol. Rep. 62: 1-14; 2010.
14. Shannon, K. Huntington's disease - clinical signs, symptoms, presympto- matic diagnosis, and diagnosis. Handb. Clin. Neurol. 100: 3013; 2011.
15. Folstein, S. E.; Chase, G. A.; Wahl, W. E.; McDonnell, A. M.; Folstein, M. F. Huntington disease in Maryland: clinical aspects of racial variation. Am. J. Hum. Genet. 41: 168-179; 1987. (Pubitemid 17145616)
16. Burns, A.; Folstein, S.; Brandt, J.; Folstein, M. Clinical assessment of irritability, aggression, and apathy in Huntington and Alzheimer disease. J. Nerv. Ment. Dis. 178: 20-26; 1990. (Pubitemid 20175040)
17. Li, S.; Schilling, G.; Young 3rd W.; Li, X.; Margolis, R.; Stine, O.; Wagster, M.; Abbott, M.; Franz, M.; Ranen, N. Huntington's disease gene (IT15) is widely expressed in human and rat tissues. Neuron 11: 985-993; 1993. (Pubitemid 23347482)
18. Vonsattel,J. P.; Myers, R. H.; Stevens,T. J.; Ferrante, R.J.; Bird, E. D.; Richarson, E. P. Jr. Neuropathological classification of Huntington's disease. J. Neuro-pathol. Exp. Neurol. 44: 559-577; 1985. (Pubitemid 16196286)
19. Vonsattel,J. P.; DiFiglia, M. Huntington disease. J. Neuropathol. Exp. Neurol. 57: 369-384; 1998.
20. Vonsattel, J. P.; Keller, C; Cortes Ramirez, E. P. Huntington's disease - neuropathology. Handb. Clin. Neurol 100: 83-100; 2011.
21. Xun, Z.; Rivera-Sánchez, S.; Ayala-Peña, S.; Lim, J.; Budworth, H.; Skoda, E.; Robbins, P.; Niedenrhofer, L; Wipf, P.; McMurray, C. Targeting of XJB-5-131 to mitochondria suppresses oxidative DNA damage and motor decline in a mouse model of Huntington's disease. Cell Rep. 2: 1137-1142; 2012.
22. Sanberg, P. R.; Fibiger, H. C; Mark, R. F. Body weight and dietary factors in Huntington's disease patients compared with matched controls. Med. J. Aust. 1: 407-409; 1981. (Pubitemid 11041471)
23. Stoy, N.; McKay, E. Weight loss in Huntington's disease. Ann. Neurol. 48: 130-131; 2000.
24. Djousse, L; Knowlton, B.; Cupples, L; Marder, K.; Shoulson, I.; Myers, R. Weight loss in early stage of Huntington's disease. Neurology 59: 1325-1330; 2002. (Pubitemid 35285981)
25. Sathasivam, K.; Hobbs, C; Turmaine, M.; Mangiarini, L; Mahal, A.; Bertaux, F; Wanker, E. E.; Doherty, P.; Davies, S. W; Bates, G. P. Formation of polyglutamine inclusions in non-CNS tissue. Hum. Mol. Genet 8: 813-822; 1999. (Pubitemid 29189048)
26. Koroshetz, W. J.; Jenkins, B. G.; Rosen, B. R.; Beal, M. F. Energy metabolism defects in Huntington's disease and effects of coenzyme Q10. Ann. Neurol. 41: 160-165; 1997. (Pubitemid 27082096)
27. Jenkins, B. G.; Koroshetz, W. J.; Beal, M. F.; Rosen, B. R. Evidence for impairment of energy metabolism in vivo in Huntington's disease using localized 1 H NMR spectroscopy. Neurology 43: 2689-2695; 1993. (Pubitemid 24004570)
28. Feigin, A.; Leenders, K.; Moeller, J.; Missimer, J.; Kuenig, G.; Spetsieris, P.; Antonini, A.; Eidelberg, D. Metabolic network abnormalities in early Huntington's disease: an [18 F]FDG PET study. J. Nucl. Med. 42: 1591-1595; 2001. (Pubitemid 33131316)
29. Ciarmiello, A.; Cannella, M.; Lastoria, S.; Simonelli, M.; Frati, L.; Rubinsztein, D.; Squitieri, F. Brain white-matter volume loss and glucose hypometabolism precede the clinical symptoms of Huntington's disease. J. Nucl. Med. 47: 215-222; 2006. (Pubitemid 46780885)
30. Brennan, W. A.; Bird, E. D.; Aprille, J. R. Regional mitochondrial respiratory activity in Huntington's disease brain. J. Neurochem. 44: 1948-1950; 1985. (Pubitemid 15047284)
31. Gu, M.; Gash, M. T; Mann, V. M.; Javoid-Agid, F.; Cooper, J. M.; Shapira, A. H. Mitochondrial defect in Huntington's disease caudate nucleus. Ann. Neurol. 39: 385-389; 1996. (Pubitemid 26100764)
32. Browne, S. E.; Bowling, A. C; MacGarvey, U.; Baik, M. J.; Berger, S. C; Muqit, M. M.; Bird, E. D.; Beal, M. F. Oxidative damage and metabolic dysfunction in Huntington's disease: selective vulnerability of the basal ganglia. Ann. Neurol. 41: 646-653; 1997. (Pubitemid 27212659)
33. Tabrizi, S.J.; Cleeter, M.; Xuereb, J.; Taanman, J. W; Cooper, J. M.; Shapira, A. H. V. Biochemical abnormalities and excitotoxicity in Huntington's disease brain. Ann. Neurol. 45: 25-32; 1999. (Pubitemid 29036428)
34. Benchoua, A.; Trioulier, Y.; Zala, D.; Gaillard, M. -C; Lefort, N.; Dufour, N.; Saudou, F.; Elalouf, J. -M.; Hirsch, E.; Hantraye, P.; Deglon, N.; Brouillet, E. Involvement of mitochondrial complex II defects in neuronal death produced by N-terminus fragment of mutated huntingtin. Mol. Biol. Cell 17: 1652-1663; 2006. (Pubitemid 44011583)
35. Butterworth, J.; Yates, C; Reynolds, G. Distribution of phosphate-activated glutaminase, succinic dehydrogenase, pyruvate dehydrogenase, and a-glutamyl transpeptidase in postmortem brain from Huntington's disease and agonal cases. J. Neurol. Sci. 67: 1352-1360; 1985.
36. Zhang, S.; Hennessey, T.; Yang, L.; Starkova, N.; Beal, M.; Starkov, A. Impaired brain creatine kinase activity in Huntington's disease. Neurodegener. Dis. 8: 194-201; 2011.
37. Perluigi, M.; Poon, H. F.; Maragos, W; Pierce, W M.; Klein, J. B.; Calabrese, V.; Cini, C; De Marco, C; Butterfield, D. A. Proteomic analysis of protein expression and oxidative modification in R6/2 transgenic mice: a model of Huntington disease. Mol. Cell. Proteomics 4: 1849-1861; 2005. (Pubitemid 41830180)
38. Ferreira, I.; Cunha-Olivera, T; Nascimiento, M.; Ribeiro, M.; Proenca, M.; Januario, C; CR, O.; Rego, A. Bioenergetic dysfunction in Huntington's disease human cybrids. Exp. Neurol. 231: 127-134; 2011.
39. Sawa, A.; Wiegand, G. W.; Cooper, J.; Margolis, R. L; Sharp, A. H.; Lawler Jr J. F; Greenamyre, J. T; Snyder, S. H.; Ross, C. A. Increased apoptosis of Huntington disease lymphoblasts associated with repeat length-dependent mitochondrial depolarization. Nat. Med 5: 1194-1198; 1999. (Pubitemid 29474426)
40. Panov, A.; Gutekunst, C; Leavitt, B.; Hayden, M.; Burke, J.; Strittmatter, W; Greenamyre, T Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines. Nat. Neurosci. 5: 731-736; 2002. (Pubitemid 34827590)
41. Seong, I. S.; Ivanova, E.; Lee, J. M.; Choo, Y S.; Fossale, E.; Anderson, M.; Gusella, J. F.; Laramie, J. M.; Myers, R. H.; Lesort, M.; MacDonald, M. E. HD CAG repeat implicates a dominant property of huntingtin in mitochondrial energy metabolism. Hum. Mol. Genet. 14: 2871-2880; 2005. (Pubitemid 41418792)
42. Squitieri, F.; Canella, M.; Sgarbi, G.; Maglione, V.; Falleni, A.; Lenzi, P.; Baracca, A.; Cislaghi, G.; Saft, C; Ragona, G.; Russo, M.; Thompson, L; Solaini, G.; Fornai, F. Severe ultrastructural mitochondrial changes in lymphoblasts homozygous for Huntington disease mutation. Mech. Ageing Dev. 127: 217-220; 2006. (Pubitemid 43165622)
43. Wang, H.; Lim, P.; Karbowski, M.; Monteiro, M. Effects of overexpression of huntingtin proteins on mitochondrial integrity. Hum. Mol. Genet. 18 : 737-752; 2009.
44. Kumar, M.; Nicholls, D.; Andersen, J. Oxidative alpha-ketoglutarate dehydro-genase inhibition via subtle elevations in monoamine oxidase B levels results in loss of spare respiratory capacity. J. Biol. Chem. 278: 46432-46439; 2003. (Pubitemid 37452214)
45. Vesce, S.; Jekabsons, M.; Johnson-Cadwell, L.; Nicholls, D. Acute glutathione depletion restricts mitochondrial ATP export in cerebellar granule neurons. J. Biol. Chem. 280: 38720-38728; 2005. (Pubitemid 43853775)
46. Yadava, N.; Nicholls, D. G. Spare respiratory capacity rather than oxidative stress regulates glutamate excitotoxicity after partial respiratory inhibition of mitochondrial complex I with rotenone. J. Neurosci. 27: 7310-7317; 2007. (Pubitemid 47037569)
47. Siddiqui, A.; Rivera-Sanchez, S.; Castro, M. d. R.; Rane, A.; Acevedo-Torres, K.; Torres-Ramos, C.; Nicholls, D.; Andersen, J.; Ayala-Torres, S. Mitochondrial DNA damage is associated with reduced mitochondrial bioenergetics in Huntington's disease. Free Radic. Biol. Med. 53: 1478-1488; 2012.
48. Lodi, R.; Schapira, A. H.; Manners, D.; Styles, P.; Wood, N. W.; Taylor, D. J.; Warner, T. T. Abnormal in vivo skeletal muscle energy metabolism in Huntington's disease and dentatorubropallidoluysian atrophy. Ann. Neurol. 48: 72-76; 200 0. (Pubitemid 30432433)
49. Saft, C.; Zange, J.; Andrich, J.; Muller, K.; Lindenberg, K.; Landwehrmeyer, B.; Vorgerd, M.; Kraus, P.; Przuntek, H.; Schols, L. Mitochondrial impairment in patients and asymptomatic mutation carriers of Huntington's disease. Mov. Disord 20; 2005. 674-670.
50. Ciammola, A.; Sassone, J.; Sciacco, M.; Mencacci, N. E.; Ripolone, M.; Bizzi, C.; Colciago, C.; Moggio, M.; Parati, G.; Silani, V.; Malfatto, G. Low anaerobic threshold and increased skeletal muscle lactate production in subjects with Huntington's disease. Mov. Disord. 26: 130-137; 2011.
51. Chaturvedi, R. K.; Adhihetty, P.; Shukla, S.; Hennessy, T.; Calingasan, N.; Yang, L.; Starkov, A.; Kiaei, M.; Cannella, M.; Sassone, J.; Ciammola, A.; Squitieri, F.; Beal, M. F. Impaired PGC-1alpha function in muscle in Huntington's disease. Hum. Mol. Genet. 18: 3048-3065; 2009.
52. Squitieri, F.; Falleni, A.; Cannella, M.; Orobello, S.; Fulceri, F.; Lenzi, P.; Fornai, F. Abnormal morphology of peripheral cell tissues from patients with Huntington disease. J. Neural Transm. 117: 77-83; 2010.
53. Ciammola, A.; Sassone, J.; Alberti, L.; Meola, G.; Mancinelli, E.; Russo, M. A.; Squitieri, F.; Silani, V. Increased apoptosis, Huntingtin inclusions and altered differentiation in muscle cell cultures from Huntington's disease subjects. Cell Death Differ. 13: 2068-2078; 2006. (Pubitemid 44742690)
54. She, P.; Zhang, Z.; Marchionini, D.; Diaz, W. C.; Jetton, T. J.; Kimball, S. R.; Vary, T. C.; Lang, C. H.; Lynch, C. J. Molecular characterization of skeletal muscle atrophy in the R6/2 mouse model of Huntington's disease. Am. J. Physiol. Endocrinol. Metab. 301:E49-61; 2011.
55. Beal, M. F. Neurochemistry and toxin models in Huntington's disease. Curr. Opin. Neurol. 7: 542-547; 1994.
56. Brouillet, E.; Jacquard, C.; Bizat, N.; Blum, D. 3-Nitropropionic acid: a mitochon-drial toxin to uncover physiopathological mechanisms underlying striatal degeneration in Huntington's disease. J. Neurochem. 95: 15 21 -1540; 2005. (Pubitemid 41804051)
57. Trushina, E.; Dyer, R. B.; Badger II J. D.; Ure, D.; Eide, L.; Tran, D. D.; Vrieze, B. T.; Legendre-Guillemin, V.; McPherson, P. S.; Mandavilli, B. S.; Van Houten, B.; Zeitlin, S.; McNiven, M.; Aebersold, R.; Hayden, M.; Parisi, J. E.; Seeberg, E.; Dragatsis, I.; Doyle, K.; Bender, A.; Chacko, C.; McMurray, C. T. Mutant Huntingtin impairs axonal trafficking in mammalian neurons in vivo and in vitro. Mol. Cell. Biol. 24: 8195-8209; 2004. (Pubitemid 39167467)
58. Tabrizi, S. J.; Workman, J.; Hart, P. E.; Mangiarini, L.; Mahal, A.; Bates, G.; Cooper, J. M.; Schapira, A. H. Mitochondrial dysfunction and free radical damage in the Huntington R6/2 transgenic mouse. Ann. Neurol. 47: 80-86; 2000. (Pubitemid 30033653)
59. Mochel, F.; Durant, B.; Meng, X.; O'Callaghan, J.; Yu, H.; Brouillet, E.; Wheeler, V.; Humbert, S.; Schiimann, R.; Durr, A. Early alterations of brain cellular energy homeostasis in Huntington's disease models. J. Biol. Chem. 287: 1361-1370; 2012.
60. Choo, Y. S.; Johnson, G. V.; MacDonald, M.; Detloff, P. J.; Lesort, M. Mutant huntingtin directly increases susceptibility of mitochondria to the calcium-induced permeability transition and cytochrome c release. Hum. Mol. Genet. 13: 1407-1420; 2004. (Pubitemid 39023049)
61. Petrassch-Parwez, E.; Nguyen, H.; Lobbecke-Schumacher, M.; Habbes, H.; Wieczorek, S.; Riess, O.; Andres, K.; Dermietzel, R.; Von Horsten, S. Cellular and subcellular localization of Hunthingtin aggregates in the brain of a rat transgenic for Huntington disease. J. Comp. Neurol. 501: 716-730; 2007.
62. Orr, A.; Li, S.; Wang, C. -E.; Li, H.; Wang, J.; Rong, J.; Xu, X.; Mastroberardino, P.; Greenamyre, T.; Li, X. -J. N-Terminal mutant Huntingtin associates with mitochondria and impairs mitochondrial trafficking. J. Neurosci. 28: 2783-2792; 2008. (Pubitemid 351398886)
63. Gunawardena, S.; Her, L. S.; Brusch, R. G.; Laymon, R. A.; Niesman, I. R.; Gordesky-Gold, B.; Sintasath, L.; Bonini, N. M.; Goldstein, L. S. Disruption of axonal transport by loss of huntingtin or expression of pathogenic polyQ proteins in Drosophila. Neuron 40: 25-40; 2003. (Pubitemid 37222462)
64. Sinadinos, C.; Burbidge-King, T.; Soh, D.; Thompson, L.; Marsh, J.; Wytten-bach, A.; Mudher, A. Live axonal transport disruption by mutant huntingtin fragments in Drosophila motor neurons. Neurobiol. Dis. 34: 389-395; 2009.
65. Milakovic, T.; Quintanilla, R. A.; Johnson, G. V. W. Mutant Huntingtin expression induces mitochondrial calcium handling defects in clonal striatal cells: functional consequences. J. Biol. Chem. 281: 34785-34795; 2006. (Pubitemid 46036517)
66. Song, W.; Chen, J.; Petrilli, A.; Liot, G.; Klinglmayr, E.; Zhou, Y.; Poquiz, P.; Tjong, J.; Pouladi, M.; Hayden, M.; Masliah, E.; Ellisman, M.; Roullier, I.; Schwarzenbacher, R.; Bossy, B.; Perkins, G.; Bossy-Wetzel, E. Mutant huntingtin binds the mitochon-drial fission GTPase Drp1 and increases its enzymatic activity. Nat. Med. 17 : 377-382; 2011.
67. Shirendeb, U.; Calkins, M.; Manczak, M.; Aneconda, V.; Dufour, B.; McBride, J.; Mao, P.; Reddy, P. Mutant huntingtin's interaction with mitochondrial protein Drp1 impairs mitochondrial biogenesis and causes defective axonal transport and synaptic degenration in Huntington's disease. Hum. Mol. Genet 21: 406-420; 2011.
68. Milakovic, T.; Johnson, G. V. Mitochondrial respiration and ATP production are significantly impaired in striatal cells expressing mutant huntingtin. J. Biol. Chem. 280: 30773-30782; 2005. (Pubitemid 41291807)
69. Boveris, A.; Chance, B. The mitochondrial generation of hydrogen peroxide. Biochemisry 132: 707-716; 1979.
70. Firdaus, W. J.; Wyttenbach, A.; Giuliano, P.; Kretz-Remy, C.; Currie, R. W.; Arrigo, A. P. Huntingtin inclusion bodies are iron-dependent centers of oxidative events. FEBS J. 273: 5428-5441; 2006. (Pubitemid 44772399)
71. Wyttenbach, A.; Sauvageot, O.; Carmichael, J.; Diaz-Latoud, C.; Arrigo, A. P.; Rubinsztein, D. C. Heat shock protein 27 prevents cellular polyglutamine toxicity and suppresses the increase of reactive oxygen species caused by huntingtin. Hum. Mol. Genet 11 : 11 37 -1151 ; 2 0 0 2 . (Pubitemid 34521094)
72. Firdaus, W.; Wyttenbach, A.; Diaz-Latoud, C.; Currie, R.; Arrigo, A. -P. Analysis of oxidative events induced by expanded polyglutamine huntingtin exon 1 that are differentially restored by expression of heat shock proteins or treatment with an antioxidant. FEBS J. 273: 3076-3093; 2006.
73. Valencia, A.; Sapp, E.; Reeves, P.; Alexander, J.; Masso, N.; Li, X. -J.; Kegel, K.; DiFligia, M. Reagents that block neuronal death from Huntington's disease also curb oxidative stress. NeuroReport 23: 10; 2011.
74. Hands, S.; Sajjad, M.; Newton, M.; Wyttenbach, A. In vitro and in vivo aggregation of a fragment of huntingtin protein directly causes free radical production. J. Biol. Chem. 286: 44512-44520; 2011.
75. Chiang, M. -C.; Chern, Y.; Huang, R. -N. PPARgamma rescue of the mitochon-drial dysfunction in Huntington's disease. Neurobiol. Dis. 45: 322-328; 2012.
76. Sorolla, M. A.; Reverter-Branchat, G.; Tamarit, J.; Ferrer, I.; Ros, J.; Cabiscol, E. Proteomic and oxidative stress analysis in human brain samples of Hunting-ton disease. Free Radic. Biol. Med. 45: 667-678; 2008.
77. Pitts, A.; Dailey, K.; Newington, J.; VChien, A.; Arseneault, R.; Cann, T.; Thompson, L.; Cumming, R. Dithiol-based compounds maintain the expression of the antioxidant protein peroxiredoxin 1 which counteracts the toxicity of mutant huntingtin. J. Biol. Chem. 287: 22717-22729; 2012.
78. Goswami, A.; Dikshit, P.; Mishra, A.; Mulherkar, S.; Nukina, N.; Jana, N. R. Oxidative stress promotes mutant huntingtin aggregation and mutant huntingtin-dependent cell death by mimicking proteasomal malfunction. Biochem. Biophys. Res. Commun. 342: 184-190; 2006. (Pubitemid 43247375)
79. del Hoyo, P.; Garcia-Redondo, A.; de Bustos, F.; Molina, J. A.; Sayed, Y.; Alonso-Navarro, H.; Caballero, L.; Arenas, J.; Jimenez-Jimenez, F. J. Oxidative stress in skin fibroblasts cultures of patients with Huntington's disease. Neurochem. Res. 31: 110 3 -1109; 2006. (Pubitemid 44379670)
80. Chen, C. M.; Wu, Y. R.; Cheng, M. L.; Liu, J. L.; Lee, Y. M.; Lee, P. W.; Soong, B. W.; Chiu, D. T. Increased oxidative damage and mitochondrial abnormalities in the peripheral blood of Huntington's disease patients. Biochem. Biophys. Res. Commun. 359: 335-340; 2007. (Pubitemid 46880509)
81. Klepac, N.; Relja, M.; Klepac, R.; Hecimovic, S.; Babic, T.; Trkulja, V. Oxidative stress parameters in plasma of Huntington's disease patients, asymptomatic Huntington's disease gene carriers and healthy subjects : a cross-sectional study. J. Neurol. 254: 1676-1683; 2007.
82. van Roon-Mom, W. M.; Pepers, B. A.; t Hoen, P. A.; Verwijmeren, C. A.; den Dunnen, J. T.; Dorsman, J. C.; van Ommen, G. B. Mutant huntingtin activates Nrf2-responsive genes and impairs dopamine synthesis in a PC12 model of Huntington's disease. BMC Mol. Biol. 9: 84; 2008.
83. Yang, L.; Calingasan, N. Y.; Thomas, B.; Chaturvedi, R. K.; Kiaei, M.; Wille, E. J.; Liby, K. T.; Williams, C.; Royce, D.; Risingsong, R.; Musiek, E. S.; Morrow, J. D.; Sporn, M.; Beal, M. F. Neuroprotective effects of the triterpenoid, CDDO methyl amide, a potent inducer of Nrf2-mediated transcription. PLoS One 4:e5757; 2009.
84. Stack, C.; Ho, D.; Wille, E.; Calingasan, N. Y.; Williams, C.; Liby, K.; Sporn, M.; Dumont, M.; Beal, M. F. Triterpenoids CDDO-ethyl amide and CDDO-trifluoroethyl amide improve the behavioral phenotype and brain pathology in a transgenic mouse model of Huntington's disease. Free Radic. Biol. Med. 49: 147 -158; 2 010 .
85. de Olivera, R.; Pais, T.; Outeiro, T. Sirtuins: common targets in aging and in neurodegeneration. Curr. Drug Targets 11 : 1270-1280; 2010.
86. Jeong, H.; Cohen, D.; Cui, L.; Supinski, A.; Savas, J.; Mazzulli, J.; TYates, J. r.; Bordone, L.; Guarente, L.; Krainc, D. Sirt1 mediates neuroprotection from mutant huntingtin by activation of the TORC1 and CREB transcriptional pathway. Nat. Med. 18: 159-165; 2011.
87. Jiang, M.; Wang, J.; Fyu, J.; Du, L.; Jeong, H.; West, T.; Xiang, L.; Peng, Q.; Hou, Z.; Cai, H.; Seredenina, T.; Arbez, N.; Zhu, S.; Sommers, K.; Qian, J.; Zhang, J.; Mori, S.; Yang, W.; Tamashiro, K.; Aja, S.; Moran, T.; Luthi-Carter, R.; Martin, B.; Maudsley, S.; Mattson, M.; Cichewicz, R.; Ross, C.; Holtzman, D.; Krainc, D.; Duan, W. Neuroprotective role of Sirt1 in mammalian models of Huntington's disease through activation of multiple Sirt1 targets. Nat. Med 18: 153-158; 2012.
88. Kong, X.; Wang, R.; Xue, Y.; Liu, X.; Zhang, H.; Chen, Y.; Fang, F.; Chang, Y. Sirtuin 3, a new target of PGC-1alpha, plays an important role in the suppression of ROS and mitochondrial biogenesis. PLoS One 5:e11707; 2010.
89. Fu, J.; Jin, J.; Cichewicz, R.; Hageman, S.; Ellis, T.; Xiang, L.; Peng, Q.; Jiang; Arbez, N.; Hotaling, K.; Ross, C.; Duan, W. Trans-(-)-e-viniferin increases mitochondrial sirtuin 3 (SIRT3), activates AMPK, and protects cells in models of Huntington's disease. J. Biol. Chem. 287: 24460-24472; 2012.
90. Solans, A.; Zambrano, A.; Rodriguez, M.; Barrientos, A. Cytotoxicity of a mutant huntingtin fragment in yeast involves early alterations in mitochon-drial OXPHOS complexes II and III. Hum. Mol. Genet 15: 3063-3081; 2006. (Pubitemid 44530710)
91. Sorolla, M. A.; Nierga, C.; Rodriguez-Colman, M. J.; Reverter-Branchat, G.; Arenas, A.; Tamarit, J.; Ros, J.; Cabiscol, E. Sir2 is induced by oxidative stress in a yeast model of Huntington disease and its activation reduces protein aggregation. Arch. Biochem. Biophys. 510: 27-34; 2011.
92. Ocampo, A.; Zambrano, A.; Barrientos, A. Suppression of polyglutamine-induced cytotoxicity in Saccharomyces cerevisiae by enhancement of mito-chondrial biogenesis. FASEB J 24: 1431-1441; 2010.
93. Puigserver, P.; Spiegelman, B. Peroxisome proliferator-activated receptor-gamma coactivator 1 alpha (PGC-1 alpha): transcriptional coactivator and metabolic regulator. Endocr. Rev 24: 78-90; 2003. (Pubitemid 36223280)
94. St-Pierre, J.; Drori, S.; Uldry, M.; Silvaggi, J. M.; Rhee, J.; Jager, S.; Handschin, C.; Zheng, K.; Lin, J.; Yang, W.; Simon, D. K.; Bachoo, R.; Spiegelman, B. M. Suppression of reactive oxygen species and neurodegeneration by the PGC-1 transcriptional coactivators. Cell 127: 397-408; 2006. (Pubitemid 44572377)
95. Cui, L.; Jeong, H.; Borovecki, F.; Parkhurst, C. N.; Tanese, N.; Krainc, D. Transcriptional repression of PGC-1alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration. Cell 127: 59-69; 2006. (Pubitemid 44466642)
96. Chaturvedi, R.; Calingasan, N.; Yang, L.; Hennessey, T.; Johri, A.; Beal, M. Impairment of PGC-1alpha expression, neuropathology and hepatic steatosis in a transgenic mouse model of Huntington's disease following chronic energy deprivation. Hum. Mol. Genet 19: 3190-3205; 2010.
97. Hathorn, T.; Snuder-Keller, A.; Messer, A. Nicotinamide improves motor deficits and upregulates PGC-1a and BDNF gene expression in a mouse model of Huntington's disease. Neurobiol. Dis 41: 43-50; 2011.
98. Tsunemi, T.; Ashe, T.; Morrison, B.; Soriano, K.; Au, J.; Roque, R.; Lazarowski, E.; Damian, V.; Masliah, E.; La Spada, A. PGC-1a rescues Huntington's disease proteotoxicity by preventing oxidative stress and promoting TFEB function. Sci. Transl. Med. 4: 142ra97; 2012.
99. Sorolla, M. A.; Rodriguez-Colman, M. J.; Tamarit, J.; Ortega, Z.; Lucas, J. J.; Ferrer, I.; Ros, J.; Cabiscol, E. Protein oxidation in Huntington disease affects energy production and vitamin B6 metabolism. Free Radic. Biol. Med. 49: 612-621; 2010.
100. Perez-Severiano, F.; Santamaria, A.; Pedraza-Chaverri, J.; Medina-Campos, O. N.; Rios, C.; Segovia, J. Increased formation of reactive oxygen species, but no changes in glutathione peroxidase activity, in striata of mice transgenic for the Huntington's disease mutation. Neurochem. Res. 29: 729 733; 2004. (Pubitemid 38429190)
101. Hersch, S. M.; Gevorkian, S.; Marder, K.; Moskowitz, C.; Feigin, A.; Cox, M.; Como, P.; Zimmerman, C.; Lin, M.; Zhang, L.; Ulug, A. M.; Beal, M. F.; Matson, W.; Bogdanov, M.; Ebbel, E.; Zaleta, A.; Kaneko, Y.; Jenkins, B.; Hevelone, N.; Zhang, H.; Yu, H.; Schoenfeld, D.; Ferrante, R.; Rosas, H. D. Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2'dG. Neurology 66: 250-252; 2006. (Pubitemid 43970166)
102. Long, J.; Matson, W.; Juhl, A.; Leavitt, B.; Paulsen, J. Investigators, P.-H.; Group, a. C. o. t. H. S. 8OHdG as a marker for Huntington disease progression. Neurobiol. Dis. 46: 625-634; 2012.
103. Beal, F. Neuroprotective effects of creatine. Amino Acids 40: 1305-1313; 2011.
104. Kovtun, I. V.; Liu, Y.; Bjoras, M.; Klungland, A.; Wilson, S. H.; McMurray, C. T. OGG1 initiates age-dependent CAG trinucleotide expansion in somatic cells. Nature 447: 447-452; 2007. (Pubitemid 46816735)
105. Bogdanov, M. B.; Andreassen, O. A.; Dedeoglu, A.; Ferrante, R. J.; Beal, M. F. Increased oxidative damage to DNA in a transgenic mouse model of Huntington's disease. J. Neurochem. 79: 1246-1249; 2001. (Pubitemid 34019802)
106. Acevedo-Torres, K.; Berrios, L.; Rosario, N.; Dufault, V.; Skatchkov, S.; Eaton, M. J.; Torres-Ramos, C. A.; Ayala-Torres, S.; Mitochondrial, DNA damage is a hallmark of chemically induced and the R6/2 transgenic model of Hunting-ton's disease. DNA Repair (Amst.) 8: 126-136; 2009.
107. Ferrante, R. J.; Andreassen, O. A.; Jenkins, B. G.; Dedeoglu, A.; Kuemmerle, S.; Kubilus, J. K.; Kaddurah-Daouk, R.; Hersch, S. M.; Beal, M. F. Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease. J. Neurosci. 20: 4389-4397; 2000. (Pubitemid 30396603)
108. Andreassen, O. A.; Dedeoglu, A.; Ferrante, R. J.; Jenkins, B. G.; Ferrante, K. L.; Thomas, M.; Friedlich, A.; Browne, S. E.; Schilling, G.; Borchelt, D. R.; Hersch, S. M.; Ross, C. A.; Beal, M. F. Creatine increases survival and delays motor symptoms in a transgenic animal model of Huntington's disease. Neurobiol. Dis. 8: 479-491; 2001. (Pubitemid 32566138)
109. Yang, L.; Calingasan, N. Y.; Wille, E. J.; Cormier, K.; Smith, K.; Ferrante, R. J.; Beal, M. F. Combination therapy with coenzyme Q10 and creatine produces additive neuroprotective effects in models of Parkinson's and Huntington's diseases. J. Neurochem. 109: 1427-1439; 2009.
110. De Luca, G.; Russo, M. T.; Degan, P.; Tiveron, C.; Zijno, A.; Meccia, E.; Ventura, I.; Mattei, E.; Nakabeppu, Y.; Crescenzi, M.; Pepponi, R.; Pezzola, A.; Popoli, P.; Bignami, M. A role for oxidized DNA precursors in Huntington's disease-like striatal neurodegeneration. PLoS Genet. 4:e1000266; 2008.
111. Yang, J. L.; Weissman, L.; Bohr, V. A.; Mattson, M. P. Mitochondrial DNA damage and repair in neurodegenerative disorders. DNA Repair (Amst.) 7: 1110-1120; 2008.
112. Polidori, M. C.; Mecocci, P.; Browne, S. E.; Senin, U.; Beal, M. F. Oxidative damage to mitochondrial DNA in Huntington's disease parietal cortex. Neurosci. Lett. 272: 53-56; 1999.
113. Liu, C.; Cheng, W. -L.; Kuo, S. -J.; Li, J. -Y.; Soong, B. -W.; Wei, Y. -H. Depletion of mitochondrial DNA in leukocytes of patients with poly-Q diseases. J. Neurol. Sci. 264: 18-21; 2008. (Pubitemid 350184064)
114. Horton, T. M.; Graham, B. H.; Corral-Debrinski, M.; Shoffner, J. M.; Kaufman, A. E.; Beal, M. F.; Wallace, D. C. Marked increase in mitochondrial DNA deletion levels in the cerebral cortex of Huntington's disease patients. Neurology 45: 1879-1883; 1995. (Pubitemid 27122962)
115. Mitra, S.; Izumi, T.; Boldogh, I.; Bhakat, K. K.; Hill, J. W.; Hazra, T. K. Choreography of oxidative damage repair in mammalian genomes. Free Radic. Biol. Med. 33: 15-28; 2002. (Pubitemid 34681002)
116. Møllersen, L.; Rowe, A.; Illuzi, J.; Hildrestrand, G.; Gerhold, K.; Tveterås, L.; Bjølgerud, A.; Wilson 3rd D.; Bjørås, M.; Klungland, A. Neil1 is a genetic modifier of somatic and germline CAG trinucleotide repeat instability in R6/1 mice. Hum. Mol. Genet 21: 4939-4947; 2012.
117. Entezam, A.; Lokanga, A.; Le, W.; Hoffman, G.; Usdin, K. Potassium bromate, a potent DNA oxidizing agent, exacerbates germline repeat expansion in a fragile X premutation mouse model. Hum. Mutat. 31: 611-616; 2010.
118. Goula, A.; Berquist, B.; Wilson, D. r.; Wheeler, V.; Trottier, Y.; Merienne, K. Stoichiometry of base excision repair proteins correlates with increased somatic CAG instability in striatum over cerebellum in Huntington's disease transgenic mice. PLosS Genet 5:e1000749; 2009.
119. Jarem, D.; Delaney, S. Premutation huntingtin allele adopts a non-B conformation and contains a hotspot for DNA damage. Biochem. Biophys. Res. Commun 416: 146-152; 2011.
120. McMurray, C. Mechanisms of trinucleotide repeat expansion during human development. Nat. Rev. Genet. 11 : 786-799; 2010.
121. Liu, Y.; Prasad, R.; Beard, W.; Hou, E.; Horton, J.; McMurray, C.; Wilson, S. Coordination between polymerase B and FEN1 can modulate CAG repeat expansion. J. Biol. Chem. 284: 28352-28366; 2009.
122. Spiro, C.; Pelletier, R.; Rolfsmeier, M. L.; Dixon, M. J.; Lahue, R. S.; Gupta, G.; Park, M. S.; Chen, X.; Mariappan, S. V.; McMurray, C. T. Inhibition of FEN-1 processing by DNA secondary structure at trinucleotide repeats. Mol. Cell 4: 1079-1085; 1999. (Pubitemid 30054913)
123. Spiro, C.; McMurray, C. Nuclease-deficient FEN-1 blocks Rad51/BRCA1-mediated repair and causes trinucleotide repeat instability. Mol. Cell. Biol 23: 6063-6074; 2003. (Pubitemid 37013086)
124. Liu, Y.; Bambara, R. Analysis of human flap endonuclease 1 mutants reveals a mechanism to prevent triplet repeat expansion. J. Biol. Chem 278: 13728-13739; 2003. (Pubitemid 36799909)
125. Manley, K.; Shirley, T. L.; Flaherty, L.; Messer, A. Msh2 deficiency prevents in vivo somatic instability of the CAG repeat in Huntington disease transgenic mice. Nat. Genet. 23: 471-473; 1999.
126. Kovtun, I. V.; McMurray, C. T. Trinucleotide expansion in haploid germ cells by gap repair. Nat. Genet. 27: 407-411; 2001. (Pubitemid 32268421)
127. Wheeler, V. C.; Lebel, L. -A.; Vrbanac, V.; Teed, A.; te Riele, H.; MacDonald, M. E. Mismatch repair gene Msh2 modifies the timing of early disease in HdhQ111 striatum. Hum. Mol. Genet 12: 273-281; 2003. (Pubitemid 36204424)
128. Dragileva, E.; Hendricks, A.; Teed, A.; Gillis, T.; Lopez, E. T.; Friedberg, E. C.; Kucherlapati, R.; Edelmann, W.; Lunetta, K. L.; MacDonald, M. E.; Wheeler, V. C. Intergenerational and striatal CAG repeat instability in Huntington's disease knock-in mice involve different DNA repair genes. Neurobiol. Dis. 33: 37-47; 2009.
129. Enokido, Y.; Tamura, T.; Ito, H.; Arumughan, A.; Komuro, A.; Shiwaku, H.; Sone, M.; Foulle, R.; Sawada, H.; Ishiguro, H.; Ono, T.; Murata, M.; Kanazawa, I.; Tomilin, N.; Tagawa, K.; Wanker, E. E.; Okazawa, H. Mutant huntingtin impairs Ku70-mediated DNA repair. J. Cell Biol. 189: 425-443; 2010.
130. Tamura, T.; Sone, M.; Iwatsubo, T.; Tagawa, K.; Wanker, E., et al. Ku70 alleviates neurodegeneration in Drosophila models of Huntington's disease. PLoS ONE 6:e27408; 2011.
131. Giuliano, P.; de Cristofaro, T.; Affaitati, A.; Pizzulo, G. M.; Feliciello, A.; Criscuolo, C.; De Michele, G.; Filla, A.; Avvedimento, E. V.; Varrone, S. DNA damage induced by polyglutamine-expanded proteins. Hum. Mol. Genet 12: 2301-2309; 2003. (Pubitemid 37160874)
132. Illuzi, J.; Yerkes, S.; Parekh-Olmedo, H.; Kmiec, E. DNA breakage and induction of DNA damage response proteins precede the appearance of visible mutant huntingtin aggregates. J. Neurosci. Res 87: 733-747; 2009.
133. Hubert, L. J.; Lin, Y.; Dion, V.; Wilson, J. Topoisomerase 1 and single-strand break repair modulate transcription-induced CAG repeat contraction in human cells. Mol. Cell. Biol. 31: 3105-3112; 2011.
134. Steffan, J. S.; Kazantsev, A.; Spasic-Boskovic, O.; Greenwald, M.; Zhu, Y. Z. G.; H; Wanker, E. E.; Bates, G. P.; Housman, D. E.; Thompson, L. M. The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription. Proc. Natl. Acad. Sci. USA, 97; 6763-6768; 2000. (Pubitemid 30412788)
135. Trettel, F.; Rigamonti, D.; Hilditch-Maguire, P.; Wheeler, V. C.; Sharp, A. H.; Persichetti, F.; Cattaneo, E.; MacDonald, M. E. Dominant phenotypes produced by the HD mutation in STHdhQ111 striatal cells. Hum. Mol. Genet 9: 2799-2809; 2000.
136. Sundararajan, R.; Freudenreich, C. Expanded CAG/CTG repeat DNA induces a checkpoint response that impacts cell proliferation in Saccharomyces cere-visiae. PLoS Genet. 7:e1001339; 2011.
137. Wilson 3rd D.; Barsky, D. The major human abasic endonuclease: formation, consequences and repair of abasic lesions in DNA. Mutat. Res. 485: 283-307; 2001. (Pubitemid 32406284)
138. Xanthoudakis, S.; Miao, G. G.; Curran, T. The redox and DNA-repair activities of Ref-1 are encoded by nonoverlapping domains. Proc. Natl. Acad. Sci. USA 91: 23-27; 1994. (Pubitemid 24018635)
139. Duguid, J. R.; Eble, J. N.; Wilson, T. M.; Kelley, M. R. Differential cellular and subcellular expression of the human multifunctional apurinic/apyrimidinic endonuclease (APE/ref-1) DNA repair enzyme. Cancer Res. 55: 6097-6102; 1995.
140. Tell, G.; Damante, G.; Caldwell, D.; Kelley, M. R. The intracellular localization of APE1/Ref-1: more than a passive phenomenon? Antioxid. Redox Signal. 7: 367-384; 2005. (Pubitemid 40279805)
141. Vasko, M. R.; Guo, C.; Kelley, M. R. The multifunctional DNA repair/redox enzyme Ape1/Ref-1 promotes survival of neurons after oxidative stress. DNA Repair (Amst.) 4: 367-379; 2005. (Pubitemid 40127000)
142. Tomkinson, A. E.; Bonk, R. T.; Linn, S. Mitochondrial endonuclease activities specific for apurinic/apyrimidinic sites in DNA from mouse cells. J. Biol. Chem. 263: 12532-12537; 1988. (Pubitemid 19000434)
143. Chattopadhyay, R.; Wiederhold, L.; Szczesny, B.; Boldogh, I.; Hazra, T. K.; Izumi, T.; Mitra, S. Identification and characterization of mitochondrial abasic (AP)-endonuclease in mammalian cells. Nucleic Acids Res. 34: 2067-2076; 2006. (Pubitemid 44314205)
144. Frossi, B.; Tell, G.; Spessotto, P.; Colombatti, A.; Vitale, G.; Pucillo, C. H(2)O (2) induces translocation of APE/Ref-1 to mitochondria in the Raji B-cell line. J. Cell Physiol. 193: 18 0 -186; 2002.
145. Pines, A.; Perrone, L.; Bivi, N.; Romanello, M.; Damante, G.; Gulisano, M.; Kelley, M. R.; Quadrifoglio, F.; Tell, G. Activation of APE1/Ref-1 is dependent on reactive oxygen species generated after purinergic receptor stimulation by ATP. Nucleic Acids Res. 33: 4379-4394; 2005. (Pubitemid 41222553)
146. Ludwig, D. L.; MacInnes, M. A.; Takiguchi, Y.; Purtymun, P. E.; Henrie, M.; Flannery, M.; Meneses, J.; Pedersen, R. A.; Chen, D. J. A murine AP-endonuclease gene-targeted deficiency with post-implantation embryonic progression and ionizing radiation sensitivity. Mutat. Res. 409: 17 -29; 1998. (Pubitemid 28467991)
147. Meira, L. B.; Devaraj, S.; Kisby, G. E.; Burns, D. K.; Daniel, R. L.; Hammer, R. E.; Grundy, S.; Jialal, I.; Friedberg, E. C. Heterozygosity for the mouse apex gene results in phenotypes associated with oxidative stress. Cancer Res. 61: 5552-5557; 2001. (Pubitemid 32694941)
148. Xanthoudakis, S.; Smeyne, R. J.; Wallace, J. D.; Curran, T. The redox/DNA repair protein, Ref-1, is essential for early embryonic development in mice. Proc. Natl. Acad. Sci. USA 93: 8919-8923; 1996. (Pubitemid 26281992)
149. Huamani, J.; McMahan, C. A.; Herbert, D. C.; Reddick, R.; McCarrey, J. R.; MacInnes, M. I.; Chen, D. J.; Walter, C. A. Spontaneous mutagenesis is enhanced in apex heterozygous mice. Mol. Cell. Biol. 24: 8145-8153; 2004. (Pubitemid 39167463)
150. Vogel, K.; Perez, M.; Momand, J.; Acevedo-Torres, K.; Hildreth, K.; Garcia, R.; Torres-Ramos, C.; Ayala-Torres, S.; Prihoda, T.; McMahan, C.; Walter, C. Age-related instability in spermatogenic cell nuclear and mitochondrial DNA obtained from apex1 heterozygous mice. Mol. Reprod. Dev. 78: 906-919; 2011. 2013)